Aeterna Zentaris Files 20-F/A Amendment

Ticker: CSCIF · Form: 20-F/A · Filed: Jul 17, 2024 · CIK: 1113423

Sentiment: neutral

Topics: amendment, annual-report, pharmaceutical

TL;DR

Aeterna Zentaris filed an amendment to its 20-F for 2023, check it for updated financials.

AI Summary

Aeterna Zentaris Inc. filed an amendment (20-F/A) on July 17, 2024, for its fiscal year ending December 31, 2023. The filing provides updated financial information and disclosures for the company, which operates in the pharmaceutical preparations sector.

Why It Matters

This amendment provides updated financial and operational disclosures for Aeterna Zentaris Inc., which is crucial for investors and stakeholders to assess the company's performance and outlook.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Aeterna Zentaris faces inherent risks related to drug development, regulatory approvals, and market competition, which are typical for the sector.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 20-F/A filing?

This 20-F/A filing is an amendment to Aeterna Zentaris Inc.'s annual report, providing updated information for the fiscal year ending December 31, 2023.

When was this amendment filed with the SEC?

The amendment was filed on July 17, 2024.

What is Aeterna Zentaris Inc.'s Standard Industrial Classification code?

Aeterna Zentaris Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.

What is the reported fiscal year end for this filing?

The reported fiscal year end is December 31, 2023.

What was the former name of Aeterna Zentaris Inc. and when did the name change occur?

The former name was AETERNA LABORATORIES INC, and the date of the name change was May 3, 2000.

Filing Stats: 4,548 words · 18 min read · ~15 pages · Grade level 14.3 · Accepted 2024-07-16 18:22:29

Key Financial Figures

Filing Documents

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F/A (Amendment No. 1) Registration Statement Pursuant to Section 12(b) or 12(g) of The Securities Exchange Act of 1934 OR Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 for the fiscal year ended December 31 , 2023 OR Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 OR Shell Company Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Commission file number 001-38064 AETERNA ZENTARIS INC. (Exact Name of Registrant as Specified in its Charter) Not Applicable (Translation of Registrant's Name into English) Canada (Jurisdiction of Incorporation) c/o Norton Rose Fulbright Canada , LLP , 222 Bay Street , Suite 3000, PO Box 53 , Toronto ON M5K 1E7 (Address of Principal Executive Offices) Gilles Gagnon President and Chief Executive Officer Aeterna Zentaris Inc. Telephone: (843) 900-3223 E-mail: ggagnon@ceapro.com c/o Norton Rose Fulbright Canada, LLP , 222 Bay Street , Suite 3000 , PO Box 53, Toronto ON M5K 1E7 , Canada (Name, Telephone, E-mail and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Shares AEZS NASDAQ Capital Market Toronto Stock Exchange Securities registered or to be registered pursuant to Section 12(g) of the Act: NONE Securities for which there is a reporting obligation pursuant to Section 15(d) of the ACT: NONE Indicate the number of outstanding shares of each of the issuer's classes of capital or common stock as at the close of the period covered by the annual report: 4,855,876 Common Shares as at December 31, 2023. Indicate by check mark whether the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No : If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes No Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definitions of "accelerated filer," "large accelerated filer," and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one): Large accelerated filer Accelerated filer Non-accelerated filer Emerging growth company If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. The term "new or revised financial accounting standard" refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012. Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to 240.10D-1(b). Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing: US GAAP International Financial Reporting Standards as issued by the Other International Accounting Standards Board If "other" has been checked in response to the previous question, indicate by check mark which fina

View Full Filing

View this 20-F/A filing on SEC EDGAR

View on Read The Filing